Lan Zhang

Dr. Lan Zhang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2019 in mAbs
Verified
Journal Article
Open access
XXXiao Xiao
Xiao Xiao
ATAimin Tang
Aimin Tang
KCKara S. Cox
Kara S. Cox
ZWZhiyun Wen
Zhiyun Wen
CCCheryl Callahan
Cheryl Callahan
LZLan Zhang
Lan Zhang
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children and older adults. Currently, no licensed vaccine is available, and therapeutic options are limited. The primary target of neutralizing antibodies to RSV is the surface fusion (F) glycoprotein. Understanding the recognition of antibodies with high neutralization potencies to RSV F antigen will provide critical insights in developing efficacious RSV antibodies and vaccines. In this study, we isolated and characterized a panel of monoclonal antibodies (mAbs) with high binding affinity to RSV prefusion F trimer and neutralization potency to RSV viruses. The mAbs were mapped to previously defined antigenic sites, and some that mapped to the same antigenic sites showed remarkable diversity in specificity, binding, and neutralization potencies. We found that the isolated site III mAbs shared highly conserved germline V-gene usage, but had different cross-reactivities to human metapneumovirus (hMPV), possibly due to the distinct modes/angles of interaction with RSV and hMPV F proteins. Furthermore, we identified a subset of potent RSV/hMPV cross-neutralizing mAbs that target antigenic site IV and the recently defined antigenic site V, while the majority of the mAbs targeting these two sites only neutralize RSV. Additionally, the isolated mAbs targeting site Ø were mono-specific for RSV and showed a wide range of neutralizing potencies on different RSV subtypes. Our data exemplify the diversity of anti-RSV mAbs and provide new insights into the immune recognition of respiratory viruses in the Pneumoviridae family.

20 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JFJessica A. Flynn
Jessica A. Flynn
EDEberhard Durr
Eberhard Durr
RSRyan Swoyer
Ryan Swoyer
PCPedro J. Cejas
Pedro J. Cejas
MHMelanie S. Horton
Melanie S. Horton
LZLan Zhang
Lan Zhang
Infection with Respiratory Syncytial Virus (RSV) causes both upper and lower respiratory tract disease in humans, leading to significant morbidity and mortality in both young children and older adults. Currently, there is no licensed vaccine available, and therapeutic options are limited. During the infection process, the type I viral fusion (F) glycoprotein on the surface of the RSV particle rearranges from a metastable prefusion conformation to a highly stable postfusion form. In people naturally infected with RSV, most potent neutralizing antibodies are directed to the prefusion form of the F protein. Therefore, an engineered RSV F protein stabilized in the prefusion conformation (DS-Cav1) is an attractive vaccine candidate. Long-term stability at 4°C or higher is a desirable attribute for a commercial subunit vaccine antigen. To assess the stability of DS-Cav1, we developed assays using D25, an antibody which recognizes the prefusion F-specific antigenic site Ø, and a novel antibody 4D7, which was found to bind antigenic site I on the postfusion form of RSV F. Biophysical analysis indicated that, upon long-term storage at 4°C, DS-Cav1 undergoes a conformational change, adopting alternate structures that concomitantly lose the site Ø epitope and gain the ability to bind 4D7.

10 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
XXXiao Xiao
Xiao Xiao
AFArthur Fridman
Arthur Fridman
LZLu Zhang
Lu Zhang
PPPavlo Pristatsky
Pavlo Pristatsky
EDEberhard Durr
Eberhard Durr
LZLan Zhang
Lan Zhang
Human metapneumovirus (hMPV) belongs to thePneumoviridaefamily and is closely related to respiratory syncytial virus (RSV). The surface fusion (F) glycoprotein mediates viral fusion and is the primary target of neutralizing antibodies against hMPV. Here we report 113 hMPV-F specific monoclonal antibodies (mAbs) isolated from memory B cells of human donors. We characterize the antibodies’ germline usage, epitopes, neutralization potencies, and binding specificities. We find that unlike RSV-F specific mAbs, antibody responses to hMPV F are less dominant against the apex of the antigen, and the majority of the potent neutralizing mAbs recognize epitopes on the side of hMPV F. Furthermore, neutralizing epitopes that differ from previously defined antigenic sites on RSV F are identified, and multiple binding modes of site V and II mAbs are discovered. Interestingly, mAbs that bind preferentially to the unprocessed prefusion F show poor neutralization potency. These results elucidate the immune recognition of hMPV infection and provide novel insights for future hMPV antibody and vaccine development.

6 June 2022 in Vaccine
Verified
Journal Article
Closed access
JFJessica A. Flynn
Jessica A. Flynn
TWTeresa Weber
Teresa Weber
PCPedro J. Cejas
Pedro J. Cejas
KCKara S. Cox
Kara S. Cox
STSinoeun Touch
Sinoeun Touch
LZLan Zhang
Lan Zhang

1 December 2018 in Vaccine
Verified
Journal Article
Closed access
LZLan Zhang
Lan Zhang
EDEberhard Durr
Eberhard Durr
JGJennifer Dawn Galli
Jennifer Dawn Galli
SCScott Cosmi
Scott Cosmi
PCPedro J. Cejas
Pedro J. Cejas
ABAndrew J. Bett
Andrew J. Bett

27 July 2016 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
ZWZhiyun Wen
Zhiyun Wen
MBMelissa A. Boddicker
Melissa A. Boddicker
RKRobin M. Kaufhold
Robin M. Kaufhold
PKPuneet Khandelwal
Puneet Khandelwal
EDEberhard Durr
Eberhard Durr
LZLan Zhang
Lan Zhang
Chlamydia trachomatis is a human pathogen which causes a number of pathologies, including genital tract infections in women that can result in tubal infertility. Prevention of infection and disease control might be achieved through vaccination; however, a safe, efficacious and cost-effective vaccine against C. trachomatis infection remains an unmet medical need. C. trachomatis major outer membrane protein (MOMP), a β-barrel integral outer membrane protein, is the most abundant antigen in the outer membrane of the bacterium and has been evaluated as a subunit vaccine candidate. Recombinant MOMP (rMOMP) expressed in E. coli cytoplasm forms inclusion bodies and rMOMP extracted from inclusion bodies results in a reduced level of protection compared to the native MOMP in a mouse challenge model. We sought to target the recombinant expression of MOMP to the E. coli outer membrane (OM). Successful surface expression was achieved with codon harmonization, utilization of low copy number vectors and promoters with moderate strength, suitable leader sequences and optimization of cell culture conditions. rMOMP was extracted from E. coli outer membrane, purified, and characterized biophysically. The OM expressed and purified rMOMP is immunogenic in mice and elicits antibodies that react to the native antigen, Chlamydia elementary body (EB). C. trachomatis MOMP was functionally expressed on the surface of E. coli outer membrane. The OM expressed and purified rMOMP elicits antibodies that react to the native antigen, Chlamydia EB, in a mouse immunogenicity model. Surface expression of MOMP could provide useful reagents for vaccine research, and the methodology could serve as a platform to produce other outer membrane proteins recombinantly.